ArticleLancet regional health. Americas2026
Burden, healthcare utilization, and costs of chronic liver disease-related hospitalizations in California: a population-based study of trends and projections, 2005-2035.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long-term trends in hospitalization burden, healthcare utilization, and costs of chronic liver disease (CLD) in the United States remain poorly characterized. Using statewide hospital discharge data, we quantified trends from 2005 to 2018 and projected future burden through 2035 across demographic subgroups. Methods: We used average annual percent change (AAPC) to quantify trends in hospitalized patients, hospitalizations, deaths, along with age-standardized rates (ASHPR, ASHR, and ASMR); hospitalizations per patient-year, average length of stay, 30-day readmission, in-hospital mortality; and inflation-adjusted hospital charges (2019 US dollars). Analyses were conducted overall and for hepatitis B virus(HBV), hepatitis C virus(HCV), alcohol-associated liver disease(ALD), and metabolic dysfunction-associated steatotic liver disease (MASLD). Findings: From 2005 to 2018, hospitalized CLD patients increased from 71,214 to 122,810 (AAPC, 4.37%; 95% CI, 3.87%-4.88%), and deaths from 11,455 to 24,560 (6.02%; 4.20%-7.86%). ASHPR increased from 275.12 to 377.88 per 100,000, and ASMR from 45.53 to 74.77. Hospitalizations and charges increased from 116,482 to 185,268 and $9.63 billion to $18.63 billion, while in-hospital mortality declined (AAPC, -7.02%; 95% CI, -8.72%-5.30%). MASLD- and ALD-related hospitalizations increased, whereas HBV- and HCV-related hospitalizations declined. Men had higher hospitalization and mortality rates, particularly for ALD. Hispanic populations had the fastest-rising burden, driven by MASLD; HBV burden was concentrated among non-Hispanic Asian populations, whereas overall CLD and ALD-related mortality were highest among non-Hispanic White populations. Interpretation: Findings highlight the need for targeted prevention and screening, early management of metabolic and alcohol-related risk factors, and equitable access to liver care. Funding: No funding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.